John Reed (Jeff Rumans for Endpoints News)

Sanofi inks ma­jor AI deal to im­prove clin­i­cal de­vel­op­ment odds with $270M cash in­vest­ment

For most of the up-and-com­ing AI play­ers in the biotech space, we’ve seen a slew of deals to uti­lize AI and ma­chine learn­ing in drug dis­cov­ery and man­u­fac­tur­ing. Com­pa­nies such as In­sil­i­co and Gen­er­ate — just to name two — have been bag­ging part­ner­ships and deals left and right.

Sanofi, though, has now lined up a new deal with one of the low­er pro­file ops in Eu­rope, go­ing with a big in­vest­ment with an eye to im­prov­ing its odds in clin­i­cal de­vel­op­ment — and the biotech in­dus­try’s newest AI deal touts a new in­gre­di­ent: fed­er­at­ed learn­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.